Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Xenios and LEUKOCARE Announce Strategic Partnership

Published: Thursday, October 03, 2013
Last Updated: Thursday, October 03, 2013
Bookmark and Share
LEUKOCARE grants exclusive license on its innovative inflammation inhibition technology and develops a generic coating to be commercialized by Xenios in various extracorporeal therapy systems.

Xenios AG and LEUKOCARE AG, two German based life science companies, have announced a strategic alliance for the development and marketing of Xenios’ extracorporeal support systems with LEUKOCARE’s anti-inflammatory surface coating.

LEUKOCARE has granted to Xenios a worldwide license of its relevant patents and know-how with exclusivity for anti-inflammatory surfaces.

Moreover, Xenios has assigned LEUKOCARE with the adaptation of the clinically proven coating technology to Xenios’ broad range of medical devices that will be commercialized under Novalung, Medos and further Xenios brands.

Anti-inflammatory coatings in Xenios’ medical devices aim to limit unwanted inflammatory responses generated by the artificial device materials to enable improved clinical outcome.

This innovative approach will be facilitated by LEUKOCARE’s proprietary Stabilizing and Protecting Solutions (SPS); these technologies represent a breakthrough in the development of biofunctional surfaces by stabilizing employed proteins, hence allowing terminal sterilization of these combination devices. This results in a higher level of product quality with significantly reduced manufacturing costs compared to aseptic production.

“With LEUKOCARE we have an innovative and ideal strategic partner to develop significantly improved medical devices. The anti-inflammatory function will allow for next generation extracorporeal devices offering tremendous improvement in all kinds of therapies conducting blood outside the human body.” said Josef Bogenschütz, CEO of Xenios.

"There is an urgent medical need to reduce inflammation in patients undergoing cardiac surgery or depending on support for a diseased lung to achieve our goal of better clinical outcomes for physicians and of course for their patients." Dr. Jürgen O. Böhm, CMMO with Xenios added.

Michael Scholl, CEO of LEUKOCARE, said: “Xenios is a strong partner: its pertinent expertise in the respective markets of extracorporeal devices and the broad range of products that will benefit from the anti-inflammatory surfaces make Xenios the perfect match for our company. This collaborative project demonstrates the full range of LEUKOCARE’s capabilities from evaluating biologically active compounds to developing marketable applications and integrating them into industrial scale processes.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

LEUKOCARE Announces EUR 3.4 M Capital Increase
Fundraising ensures further execution of license-based business model.
Tuesday, September 03, 2013
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!